Coronary Risk Factors in Maintenance Hemodialysis Patients: Who is the Culprit - Hemodialysis or Chronic Renal Failure?

Overview

Journal Int J Appl Basic Med Res

Specialty General Medicine

Date 2013 Jun 19

PMID 23776765

Authors

Kapil Gupta

Rajiv Mahajan

Affiliations

Soon will be listed here.

Abstract

Objective: Dyslipidemia, common in uremic patients subjected to maintenance hemodialysis (HD), represents an independent risk factor for atherosclerosis; but the association between long-term HD and uremic dyslipidemia is not crystal clear. The present study was aimed to ascertain any association.

Materials And Methods: The effects of chronic renal failure (CRF) and HD duration on serum lipids, lipoproteins and homocysteine (HC) were studied in 84 patients suffering from CRF subjected to maintenance HD and were compared with 68 healthy, age-, sex- and race-matched control cohorts.

Results: Increase in serum free cholesterol (FC), triglycerides, very low-density lipoprotein cholesterol and HC levels, and decrease in esterified cholesterol (EC), EC/FC ratio, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol levels were highly significant (P < 0.001) in pre-dialysis patients compared to controls. Further disturbances were observed (P < 0.05) by repeated HD, resulting in further significant increase in FC, and decrease in EC/FC ratio and HDL-C levels after 40 dialysis schedules.

Conclusion: Levels of HDL-C, plasma FC, and ratio of EC/FC appeared to be clearly altered by HD duration, submitting patients to a greater risk of atherosclerosis due to maintenance HD.

References

Righetti M . Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Clin Chem Lab Med. 2007; 45(12):1586-9. DOI: 10.1515/CCLM.2007.335. View

Maheshwari N, Ansari M, Darshana M, Lal K, Ahmed K . Pattern of lipid profile in patients on maintenance hemodialysis. Saudi J Kidney Dis Transpl. 2010; 21(3):565-70. View

Paragh G, Balogh Z, MATYUS J, Karpati I, Ujhelyi L, Kakuk G . Lipid abnormalities in uraemic patients on chronic haemodialysis. Acta Med Hung. 1992; 49(3-4):207-17. View

Jakic M, Lovcic V, Klaric D, Mihaljevic D, Zibar L, Jakic M . Are lipoprotein disturbances in chronic hemodialyzed patients only renal failure related?. Coll Antropol. 2010; 34 Suppl 1:181-8. View

Bellan L, Mikelberg F, Frohlich J . Lecithin:cholesterol acyltransferase deficiency. Can J Ophthalmol. 1988; 23(6):285-7. View

Dieplinger H, Schoenfeld P, Fielding C . Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest. 1986; 77(4):1071-83. PMC: 424441. DOI: 10.1172/JCI112406. View

APPEL G . Lipid abnormalities in renal disease. Kidney Int. 1991; 39(1):169-83. DOI: 10.1038/ki.1991.22. View

Lowenstein J, Neusy A . Effects of prazosin and propranolol on serum lipids in patients with essential hypertension. Am J Med. 1984; 76(2A):79-84. DOI: 10.1016/0002-9343(84)90960-4. View

Smolders B, Lemmens R, Thijs V . Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke. 2007; 38(6):1959-66. DOI: 10.1161/STROKEAHA.106.480657. View

10.

Chan M, Ramdial L, Varghese Z, Persaud J, Baillod R, Moorhead J . Plasma lecithin-cholesterol acyltransferase activities in uraemic patients. Clin Chim Acta. 1982; 119(1-2):65-72. DOI: 10.1016/0009-8981(82)90405-3. View

11.

Ifudu O, Brezsnyak W, Reydel C, McClendon E, Surgrue T, DiRienzo R . Pathobiology and functional status of long-term hemodialysis patients. Am J Nephrol. 1995; 15(5):379-85. DOI: 10.1159/000168870. View

12.

McGowan M, Artiss J, Strandbergh D, ZAK B . A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983; 29(3):538-42. View

13.

Akdag I, Yilmaz Y, Kahvecioglu S, Bolca N, Ercan I, Ersoy A . Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: a 5-year prospective study. Nephron Clin Pract. 2008; 108(2):c99-c105. DOI: 10.1159/000113526. View

14.

Refsum H, Smith A, Ueland P, Nexo E, Clarke R, McPartlin J . Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004; 50(1):3-32. DOI: 10.1373/clinchem.2003.021634. View

15.

Zlatkis A, ZAK B, Boyle A . A new method for the direct determination of serum cholesterol. J Lab Clin Med. 1953; 41(3):486-92. View

16.

Mekki K, Prost J, Bouchenak M, Remaoun M, Belleville J . Plasma lipoprotein lipase, hepatic lipase activities, VLDL, LDL compositions at different times of hemodialysis. Atherosclerosis. 2003; 169(2):269-77. DOI: 10.1016/s0021-9150(03)00011-x. View

17.

Chan D, Irish A, Dogra G, Watts G . Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis. 2007; 196(2):823-34. DOI: 10.1016/j.atherosclerosis.2007.01.023. View

18.

Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H . Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int. 1992; 41(6):1653-61. DOI: 10.1038/ki.1992.238. View

19.

Mekki K, Bouchenak M, Lamri M, Remaoun M, Belleville J . Changes in plasma lecithin: cholesterol acyltransferase activity, HDL(2), HDL(3) amounts and compositions in patients with chronic renal failure after different times of hemodialysis. Atherosclerosis. 2002; 162(2):409-17. DOI: 10.1016/s0021-9150(01)00728-6. View

20.

Toborek M, Wasik T, Drozdz M, Klin M . Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism. 1992; 41(11):1229-32. DOI: 10.1016/0026-0495(92)90014-2. View